Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOXIA02 hepatic arterial infusion gemcitabine + oxaliplatin in second-line unresectable intrahepatic cholangiocarcinoma
2024-519132-17-00Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Objective response rate at 4 months. Started Jan 2025; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-519132-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519132-17-00.